RDF/XML JSON-LD N3/Turtle RDF/JSON

Fernández López, Cristina Author

Analyzing the clinical benefit of newer therapies for advanced or metastatic non-small-cell lung cancer: application of the ESMO-magnitude of clinical benefit scale v1.1

  • Ricardo García-Fumero
  • Cristina Fernández-López
  • Miguel Ángel Calleja-Hernández
  • José Expósito-Hernández

ACTA ONCOLOGICA - 29/06/2021

10.1080/0284186x.2021.1942546

Cite count: 2 (Web of Science)
  • JCR Impact Factor: 4.311 (2021)
  • JCR 5-year Impact Factor: 4.338
  • JCR Categories: ONCOLOGY

Trends in endpoint selection and result interpretation in advanced non‐small cell lung cancer clinical trials published between 2000 and 2012: A retrospective cohort study

  • Cristina Fernández‐López
  • Miguel Ángel Calleja‐Hernández
  • Jaime Espín Balbino
  • José Cabeza‐Barrera
  • José Expósito‐Hernández

Thoracic Cancer - 04/2019

10.1111/1759-7714.13024

Cite count: 2 (Web of Science)
  • SJR Quartile: Q2
  • JCR Impact Factor: 2.61 (2019)
  • JCR 5-year Impact Factor: 2.402
  • JCR Categories: RESPIRATORY SYSTEM
  • SJR Categories: Medicine (miscellaneous) (Q2); Pulmonary and Respiratory Medicine (Q2); Oncology (Q3)

Trends in phase III randomized controlled clinical trials on the treatment of advanced non‐small‐cell lung cancer

  • Fernandez-Lopez, Cristina
  • Exposito-Hernandez, Jose
  • Pedro Arrebola-Moreno, Juan
  • Angel Calleja-Hernandez, Miguel
  • Exposito-Ruiz, Manuela
  • Guerrero-Tejada, Rosa
  • Linares, Isabel
  • Cabeza-Barrera, Jose
... View more Collapse

Cancer Medicine - 09/2016

10.1002/cam4.782

Cite count: 8 (Web of Science)
  • SJR Quartile: Q1
  • JCR Impact Factor: 3.362 (2016)
  • JCR 5-year Impact Factor: 3.492
  • JCR Categories: ONCOLOGY
  • SJR Categories: Oncology (Q1); Radiology, Nuclear Medicine and Imaging (Q1); Cancer Research (Q2)

Seguridad de boceprevir y telaprevir en la práctica clínica habitual

FARMACIA HOSPITALARIA - 1/01/2014

10.7399/fh.2014.38.1.1142

  • SJR Quartile: Q3
  • SJR Categories: Medicine (miscellaneous) (Q3); Pharmacology (Q3)
  • ORCID

A new fractioning process to decrease the price of ranibizumab

  • Gonzalez-Andrades, Miguel
  • Ignacio Munoz-Avila, Jose
  • Medarde-Caballero, Catalina
  • Fernandez-Lopez, Cristina
  • Damas-Alonso, Miguel

Acta Ophthalmologica - 12/2012

10.1111/j.1755-3768.2012.02433.x

  • SJR Quartile: Q1
  • JCR Impact Factor: 2.345 (2012)
  • JCR 5-year Impact Factor: 2.428
  • JCR Categories: OPHTHALMOLOGY
  • SJR Categories: Medicine (miscellaneous) (Q1); Ophthalmology (Q1)

This author has no books, chapters or theses.

This author has no conferences.

This author has no patents.

This author has no reports or other types of publications.

Last data update: 4/27/24 9:05 AM
Next scheduled update: 5/4/24 3:00 AM